Compare Align Technology, Inc. (ALGN) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Morgan Stanley — how do they compare? Align Technology, Inc. trades at $172.72 (market cap $12.51B), while Morgan Stanley trades at $216.3 (market cap $338.50B). The key difference: Morgan Stanley is far larger — about 27.1× Align Technology, Inc.'s market cap, and Morgan Stanley pays a 2.14% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | MS | |
|---|---|---|
Market Cap | $12.51B | $338.50B |
Sector | Health | Financials |
52-Week High | $197.51 | $228.42 |
52-Week Low | $124.88 | $144.04 |
Enterprise Value | $11.52B | — |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.66, up 2.71% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $2.64 surpassing the $2.62 estimate. Revenue reached a record $1.06 billion in Q2 2026, driven by clear aligner growth. Recent board changes and strategic initiatives aim to enhance long-term value.
The outlook is positive, supported by robust fundamentals and institutional interest, but risks include competitive pressures and scanner segment weakness. Valuation multiples remain below historical peaks, offering potential upside if growth accelerates. Investor sentiment is cautiously optimistic amid ongoing operational reviews.
Morgan Stanley (MS) trades at $215.1, down 0.54% on the day, with a neutral technical signal and key support at $214. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.46 surpassing expectations of $2.89. Revenue growth accelerated to $66.0B in 2025, and net income margin improved to 25.56%. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive with a consensus price target of $239.58, implying 11% upside. Strengths include robust profitability and strategic initiatives, but risks involve volatile cash flows from operations and high leverage. Analyst sentiment is bullish with 56% buy ratings, though investors should monitor debt levels and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
